Table 1.
Recombinant Proteins Expressed Using Ad Vectors and Yields Obtained
| Protein expressed | Position | Serotype | Promoter | Cell linea | Yieldb | Reference |
|---|---|---|---|---|---|---|
| Human α1antitrypsinc | El | Ad5 | MLP + TPL | HeLa | 6 μg/ml/106 cells | Gilardi et al. (1990) |
| Human α1-antitrypsnvc | El | Ad5 | MLP | HUVEC | 0.3–0.6 μg/106 cells/day | Lemarchand et al. (1992) |
| β-Galactosidase | El | Ad5 | CMV | MRC5 | 27 μg/6 cm dishd | Wilkinson and Akrigs (1992) |
| Luciferase | E3 | Ad5e | SV40 early | HeLa | 20 μg/106 cells | Mittal et al. (1993) |
| PTP1C protein tyrosine phosphatase | El | Ad5 | MLP + TPL | 293 S | 90 mg/liter | Garnier et al. (1994) |
| PTP1C protein tyrosine phosphatase | El | Ad5 | MLP + TPL | 293 | 100 μg/150 mm dish | Zhao et al. (1993) |
| HBsAgc | El | Ad5 | E1a | Vero | 0.5–1 μg/106 cells | Ballay et al. (1985) |
| HBsAg | E4/ITR | Ad4e, Ad7e | MLP + TPL | A549 | 3–4 μg/106 cells | Mason et al. (1990) |
| HbsAgc and IL-6c | E4/ITR, E3 | Ad7e | MLP + TPL, E3 | A549 | 8–10 μg/106 cells, 0.1–0.2 μg/106 cells | Lindley et al. (1994) |
| Hepatitis B precore antigen,c HbSAgc | E3, E4/ITR | Ad7e | E3, MLP + TPL | A549 | 1.4 μg, 6 μg /106 cells | Ye et al. (1991) |
| Measles virus N protein | El | Ad5 | CMV | MRC5 | 20% of soluble cell proteinb | Fooks et al. (1995) |
| Porcine respiratory coronavirus spike glycoprotein | E3 | Ad5 | E3 | ST | 33 μg/106 cells | Callebaut and Pensaert (1995) |
| HTV-1 env | E3 | Ad5e | E3 | HeLaS | 1 mg/liter of culture | Dewar et al. (1989) |
| HIV-1 env | E4/ITR | Ad7e | MLP + TPL | A549 | 4 μg/106 cells | Chanda et al. (1990) |
| Polyomavirus middle T antigen | El | Ad5 | MLP + TPL | 293 | 100 μg/100-mm dish | Schaffhausen et al. |
| Murine IL-12 (both subunits)c | El, E3 | Ad5 | CMV, CMV | 293 | 42,000 U/106 cells/day | Bramson et al. (1996) |
| Soluble ciliary neurotrophic factorc | El | Ad5 | RSV LTR | 1° rat astrocytes | 120 pg/106 cells/hr | Smith et al. (1996) |
| Neurotrophin-3c | El | Ad5 | RSV LTR | 1° rat astrocytes | 350 pg/106 cells/hr | Smith et al. (1996) |
| Fibroblast growth factor 4 | El | Ad5 | Sr α | Dami | 2–3 μg/106 cells | Konishi et al. (1996) |
| Human IL-2c | El | Ad5 | CMV | Various human | 1–2 μg/106 cells | Addison et al. (1995) |
| VEGFc | El | Ad5 | CMV | HUVEC | 2.2 μg/106 cells/day | Mühlhauser et al. (1995) |
| GM-CSFc | El | Ad5 | CMV | 293 | 8 μg/106 cells | Xing et al. (1996) |
HeLa, human cervical carcinoma cells; A549, human lung carcinoma; HUVEC, primary human vascular endothelial cells; MRC5, human fibroblasts; 293, Ad5-transformed human embryonic kidney cell line; 293S, suspension subline of 293; Vero, monkey kidney cell line; ST, swine testicle cell line; Dami, human megakaryocytic cell line.
Yields reported by the authors were converted to μg recombinant protein/106 cells.
Secreted to medium.
Forskolin induced.
Nondefective vector.